People: Novartis AG (NOVN.VX)

NOVN.VX on Virt-X Level 1

90.15CHF
30 Jan 2015
Change (% chg)

CHF-0.85 (-0.93%)
Prev Close
CHF91.00
Open
CHF91.40
Day's High
CHF91.60
Day's Low
CHF90.05
Volume
8,153,913
Avg. Vol
7,144,794
52-wk High
CHF99.75
52-wk Low
CHF70.15

Search Stocks

Wiedeking, Wendelin 

Brief Biography

Dr. Wendelin Wiedeking has been Member of the Board of Directors at Novartis AG since 2003. He qualifies as an independent Non-Executive Director. He is Member of the Audit and Compliance Committee and the Risk Committee of the Company. Dr. Wiedeking was Chairman of the Executive Board of Porsche Automobil Holding SE and of Dr. Ing. h.c. F. Porsche AG, both in Germany until July 2009. Since then he has been an entrepreneur. His professional career began in 1983 in Germany as Director’s Assistant in the Production and Materials Management area of Dr. Ing. h.c. F. Porsche AG in Stuttgart-Zuffenhausen. In 1988, he moved to Glyco Metall-Werke KG in Wiesbaden as Division Manager, where he advanced by 1990 to the position of Chief Executive Officer and Chairman of the Board of Management of Glyco AG. In 1991, he returned to Dr. Ing. h.c. F. Porsche AG as Production Director. A year later, the Supervisory Board appointed him Spokesman of the Executive Board (CEO), and Chairman in 1993. Dr. Wiedeking graduated in mechanical engineering in 1978 and worked as a scientific assistant in the Machine Tool Laboratory of the Rhine-Westphalian College of Advanced Technology in Germany.

Basic Compensation

Total Annual Compensation, CHF Long-Term Incentive Plans, CHF All Other, CHF Fiscal Year Total, CHF
450,040 -- 26,893 476,933

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Joerg Reinhardt

1,900,810

Joseph Jimenez

13,226,300

Ulrich Lehner

1,328,210

Harry Kirsch

2,344,290

Peter Kornicker

--

Felix Ehrat

4,321,510
As Of 30 Dec 2013
Search Stocks